

Table 3 Antigens of human leukocyte antigen (HLA) class I and II regions showing significant difference between ulcerative colitis patients and controls

HLA antigens	Ulcerative colitis (<i>n</i> = 50)		Controls (<i>n</i> = 67)		Odds ratio	EF or PF	<i>P</i> -value ^a	95% CI
	No.	%	N	%				
A3	13	26.0	6	8.9	3.57	0.19	0.03	1.13–12.36
A9	22	44.0	12	17.9	3.60	0.32	0.004	1.45–9.15
A11	2	4.0	15	22.4	0.14	0.20	0.008	0.02–0.68
A30	2	4.0	14	20.9	0.16	0.18	0.01	0.02–0.75
B41	36	72.0	4	6.0	40.50	0.70	< 0.001	11.40–173.87
DR4	18	36.0	9	13.4	3.63	0.26	0.008	1.35–10.18
DR5	8	16.0	2	3.0	6.19	0.13	0.03	1.14–61.69
DR7	3	6.0	16	23.9	0.20	0.19	0.02	0.04–0.79
DR8	14	28.0	6	9.0	3.95	0.21	0.01	1.27–13.55
DQ1	20	40.0	12	17.9	2.94	0.26	0.02	1.17–7.54
DQ2	13	26.0	7	10.4	3.01	0.17	0.05	1.00–9.69

^aFisher exact test.

n = total number of patients; EF = etiological fraction, PF = preventive fraction, CI = confidence interval.